QuinnCT. Clinical severity in sickle cell disease: the challenges of definition and prognostication. Exp Biol Med2016; 241: XX–XX.
2.
HabaraASteinbergMH. Genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med2016; 241: XX–XX.
3.
BraghiniCACostaFCFedosyukHNeadesRYNovikovaLVParkerMPWinefieldRDPetersonKR. Generation of non-deletional hereditary persistence of fetal hemoglobin (HPFH) β-YAC transgenic mouse models: -175 Black HPFH and -195 Brazilian HPFH. Exp Biol Med2016; 241: XX–XX.
4.
LiuLPertsemlidisADingL-HStoryMDSteinbergMSebastianiPHoppeCBallasSKPaceBS. A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease. Exp Biol Med2016; 241: XX–XX.
5.
WardCMLiBPaceBS. Stable expression of miR-34a mediates fetal hemoglobin induction in K562 cells. Exp Biol Med2016; 241: XX–XX.
6.
WangW. Prognostic factors and the response to hydroxurea treatment in sickle cell disease. Exp Biol Med2016; 241: XX–XX.
7.
Ginter SummarellCCSheehanVA. Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. Exp Biol Med2016; 241: XX–XX.
8.
PahlKMullenCA. Acute chest syndrome in sickle cell disease: effect of genotype and asthma. Exp Biol Med2016; 241: XX–XX.
9.
HankinsJPenkertRRLavoiePTangLSunYHurwitzJL. Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Exp Biol Med2016; 241: XX–XX.
10.
RiveraCPVenezianiAWareREPlattMO. Sickle cell anemia and pediatric strokes: computational fluid dynamics analysis in the middle cerebral artery. Exp Biol Med2016; 241: XX–XX.
11.
TanFGhoshSMosunjacMManciEOfori-AcquahSF. Diametric effects of hypoxia on pathophysiology of sickle cell disease in a murine model. Exp Biol Med2016; 241: XX–XX.
12.
GoodmanSRPaceBSHansenKCD’alessandroAXiaYDaescuOGlattSJ. Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: early steps to precision medicine. Exp Biol Med2016; 241: XX–XX.
